研究报道

红细胞单采术治疗高原红细胞增多症合并高尿酸血症

展开
  • 1.上海交通大学医学院附属瑞金医院血液科,上海 200025
    2.日喀则市人民医院血液科,西藏自治区 日喀则 857000

收稿日期: 2021-01-26

  网络出版日期: 2022-07-25

本文引用格式

祝洪明, 李啸扬, 普布旺堆, 巴顿, 方洁, 次仁央宗, 宗吉, 乐飞, 罗布卓玛 . 红细胞单采术治疗高原红细胞增多症合并高尿酸血症[J]. 内科理论与实践, 2021 , 16(04) : 267 -269 . DOI: 10.16138/j.1673-6087.2021.04.009

参考文献

[1] Villafuerte FC, Corante N. Chronic mountain sickness: clinical aspects, etiology, management, and treatment[J]. High Alt Med Biol, 2016, 17(2): 61-69.
[2] León-Velarde F, Maggiorini M, Reeves JT, et al. Consensus statement on chronic and subacute high altitude diseases[J]. High Alt Med Biol, 2005, 6(2): 147-157.
[3] Dong Y, Dun B, Wang Dui PB, et al. Therapeutic erythrocytapheresis is effective in treating high altitude polycythemia on the Qinghai-Tibet plateau[J]. Wilderness Environ Med, 2020, 31(4): 426-430.
[4] Rombout-Sestrienkova E, Winkens B, van Kraaij M, et al. A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naive hereditary hemochromatosis[J]. J Clin Apher, 2021, 36(3): 340-347.
[5] 何文华. 干扰素联合羟基脲治疗真性红细胞增多症的疗效观察[J]. 医药前沿, 2012, 2(9): 86.
[6] Evers D, Kerkhoffs JL, Van Egmond L, et al. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy in relation to blood volume and delta-hematocrit: an evaluation in hereditary hemochromatosis polycythemia vera and secondary erythrocytosis[J]. Transfus Apher Sci, 2013, 48(2): 187.
[7] 方洁, 李啸扬, 李军民, 等. 红细胞单采治疗高原红细胞增多症合并凝血功能异常的临床观察[J]. 实用心脑肺血管病杂志, 2019, 27(S2): 44-46.
[8] 朱澍, 罗布卓玛, 方洁, 等. 西藏地区红细胞单采治疗高原红细胞增多症的疗效研究[J]. 重庆医学, 2021, 50(3): 454-457.
[9] Rombout-Sestrienkova E, Nieman FH, Essers BA, et al. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial[J]. Transfusion, 2012, 52(3): 470-477.
[10] Jefferson JA, Escudero E, Hurtado ME, et al. Hyperuricemia,hypertension, and proteinuria associated with high-altitude polycythemia[J]. Am J Kidney Dis, 2002, 39(6): 1135-1142.
[11] McCord JM. Oxygen-derived free radicals in postischemic tissue injury[J]. N Engl J Med, 1985, 312(3): 159-163.
[12] Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles[J]. J Pharmacol Exp Ther, 1997, 280(2): 839-845.
[13] 王琰, 努尔曼古丽, 王引虎, 等. 进驻不同海拔高原健康男青年肾功能的变化[J]. 西南国防医药, 2011, 21(1): 24-26.
[14] Yang M, Cui S, Wuren T, et al. Ureteral calculi associated with high-altitude polycythemia[J]. Medicine (Baltimore), 2021, 100(7): e24621.
[15] Hao Y, Reyes LT, Morris R, et al. Changes of protein levels in human urine reflect the dysregulation of signaling pathways of chronic kidney disease and its complications[J]. Sci Rep, 2020, 10(1): 20743.
[16] Vargas-Santos AB, Neogi T. Management of gout and hyperuricemia in CKD[J]. Am J Kidney Dis, 2017, 70(3): 422-439.
文章导航

/